Browse diseases

…onsidering deprescribing is critical. Medication discrepancies (MDs) during care transitions can compromise patient safety, as over…

… bone marrow aspiration in up to 40% of patients with suspected MDS.Trials registration number NCT04399018.…

…angements can present either myelodysplastic neoplasms (MDS) or acute myeloid leukaemia (AML), both associated with dismal prognosis. The 2022 WHO clas…

… cells to CD1d-expressing hematological malignancies, including multiple myeloma (MM) and acute myeloid leukemia (AML). Here, we evaluated wheth…

…y. Furthermore, 44% of AML with KMT2A-PTD could be diagnosed as AML-MR based on cytogenetics or genomics. We observed progenitor abnor…

… commonly used for treating myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). There is conflicting evidence regarding its impact on ca…

…For patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS), posaconazole for funga…

…quantify the proportion of patients with ≥1 MD or unintentional MD (UMD) across care transitions. Secondary aims included assessin…

…ollowing CAR-T therapy in patients with leukemia, lymphoma, and myeloma.Methods MEDLINE, Embase, Web of Science, and Cochrane CENTRAL d…

…acute myeloid leukaemia (AML) (1%–19% blasts) and 71% (351/495) AML (≥20% blasts), with 18% (81/460) having low CK50. Overall, 83% …